Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network

Autor: Lm, Mcshane, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Yves Fradet, Hb, Grossman, Peng A, Se, Taube, Fm, Waldman

Publikováno v: Europe PubMed Central

The National Cancer Institute Bladder Tumor Marker Network conducted a study to evaluate the reproducibility of immunohistochemistry for measuring p53 expression in bladder tumors. Fifty paraffin blocks (10 from each of the five network institutions)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::db3504eda95a8ac2c7daa140bebabc99
http://europepmc.org/abstract/med/10815908

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.

Autor: Gien LT; Odette Cancer Centre-Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Song Z; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Poklepovic A; Virginia Commonwealth University/Massey Cancer Center, Richmond, VA., Collisson EA; Fred Hutchinson Cancer Center, Seattle, WA., Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD.; Deceased., Hamilton SR; City of Hope National Medical Center, Duarte, CA., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX., Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center; Boston, MA.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2024 Dec; Vol. 8, pp. e2400514. Date of Electronic Publication: 2024 Dec 12.

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors.

Autor: Krushkal J; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Zhao Y; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Roney K; Department of Biostatistics and Bioinformatics, George Washington University, Washington, DC, USA., Zhu W; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Brooks A; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Wilsker D; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Publikováno v: Epigenetics [Epigenetics] 2024 Dec; Vol. 19 (1), pp. 2309824. Date of Electronic Publication: 2024 Feb 18.

Phase 2 Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1C.

Autor: O'Hara MH; University of Pennsylvania, Philadelphia, PA, United States., Jegede O; Dana-Farber Cancer Institute, Boston, MA, United States., Dickson MA; Memorial Sloan Kettering Cancer Center, New York, NY, United States., DeMichele AM; University of Pennsylvania School of Medicine, Philadelphia, PA, United States., Piekarz R; National Cancer Institute, Bethesda, MD, United States., Gray RJ; DFCI, Boston, MA, United States., Wang V; Dana-Farber Cancer Institute, United States., McShane LM; National Institutes of Health, Bethesda, MD, United States., Rubinstein LV; National Institutes of Health, National Cancer Institute, Bethesda, MD, United States., Patton DR; National Cancer Institute, Bethesda, MD, United States., Williams PM; Frederick National Laboratory for Cancer Research, United States., Hamilton SR; City of Hope, Duarte, California, United States., Onitilo A; Wisconsin NCORP, Weston, Wisconsin, United States., Tricoli JV; National Cancer Institute, Rockville, MD, United States., Conley BA; National Cancer Institute, Northport, MI, United States., Arteaga CL; The University of Texas Southwestern Medical Center, Dallas, Texas, United States., Harris LN; National Cancer Institute, Rockville, MD, United States., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA, United States., Chen AP; National Cancer Institute, Bethesda, MD, United States., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA, United States.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 22. Date of Electronic Publication: 2024 Oct 22.

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.

Autor: Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lloyd MW; The Jackson Laboratory, Bar Harbor, Maine., Koc S; Seven Bridges Genomics, Charlestown, Massachusetts., Evrard YA; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., McShane LM; Biometric Research Program, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Lewis MT; Departments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Li D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rubinstein L; Biometric Research Program, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Welm A; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Dean DA 2nd; Seven Bridges Genomics, Charlestown, Massachusetts., Srivastava A; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut., Grover JW; Seven Bridges Genomics, Charlestown, Massachusetts., Ha MJ; Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Republic of Korea., Chen H; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Varadarajan K; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Roth JA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Welm B; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Govinden R; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri., Ding L; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri., Kaochar S; Department of Medicine, Baylor College of Medicine, Houston, Texas., Mitsiades N; Department of Molecular Cellular Biology, Baylor College of Medicine, Houston, Texas., Carvajal-Carmona L; Department of Biochemistry and Molecular Medicine, University of California, Davis, California., Herylyn M; The Wistar Institute, Philadelphia, Pennsylvania., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Fields R; Department of Surgery, Washington University School of Medicine, St. Louis, Missouri., Trevino JG; Department of Surgery, Virginia Commonwealth University, Richmond, Virginia., Harrell JC; Department of Pathology, Virginia Commonwealth University, Richmond, Virginia., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Chuang JH; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut., Moscow JA; Investigational Drug Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Jul 02; Vol. 23 (7), pp. 924-938.